IL-13
Interleukin-13 (IL-13) is a type 2 cytokine primarily produced by Th2 cells, regulating immune responses through modulation of macrophage and epithelial cell activity[1]. Mechanistically, IL-13 signals via the IL-4 receptor alpha (IL-4Rα)/IL-13Rα1 heterodimer, activating the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, particularly STAT6, to induce gene expression associated with allergic inflammation and tissue remodeling[2][3]. In disease models such as experimental autoimmune encephalomyelitis (EAE), IL-13 exerts anti-inflammatory effects by suppressing Th1 and Th17-mediated neuroinflammation, highlighting its role in immune regulation and potential neuroprotective function[4][5]. Compared with related isoforms like IL-4, IL-13 demonstrates distinct receptor-binding affinities and downstream signaling kinetics, which influence the magnitude and specificity of cellular responses[6]. Pharmacological agonists of IL-13 or IL-13R pathways have been employed experimentally to modulate immune cell polarization and cytokine production, whereas IL-13 neutralizing antibodies are utilized to dissect isoform-specific effects in inflammatory models[1][6]. These experimental applications provide insight into IL-13’s selective regulation of immune pathways, offering mechanistic understanding and design considerations for cytokine-targeted interventions in autoimmune and allergic diseases[2].
References:
- [1]. Mannie MD, et al. Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis. Front Immunol. 2012 Aug 20;3:255. [Content Brief]
- [2]. Liu Y, et al. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J Immunol. 2014 Jan 1;192(1):59-72. [Content Brief]
- [3]. Benveniste EN, et al. Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis. J Interferon Cytokine Res. 2014 Aug;34(8):577-88. [Content Brief]
- [4]. Peón AN, et al. Helminth Products Potently Modulate Experimental Autoimmune Encephalomyelitis by Downregulating Neuroinflammation and Promoting a Suppressive Microenvironment. Mediators Inflamm. 2017;2017:8494572. [Content Brief]
- [5]. Johnson BM, et al. STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways. J Immunol. 2021 May 1;206(9):2015-2028. [Content Brief]
- [6]. Vandenbroeck K, et al. Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J Pharm Pharmacol. 2004 Feb;56(2):145-60. [Content Brief]
-
IL-13 Related Products (56)
Related Products (56)
-
Recombinant Proteins (19)
-
Keap1-Nrf2 PPI-IN-2
0 ImagesCat. No.: HY-189433Keap1-Nrf2 PPI-IN-2 is a Keap1-Nrf2 PPI inhibitor with an EC50 of 14.2 μM. Keap1-Nrf2 PPI-IN-2 covalently binds to Keap1 cysteine residues through its electrophilic itaconate moiety, disrupts the Keap1-Nrf2 protein-protein interaction, releases Nrf2, and promotes its nuclear translocation and antioxidant gene expression, thereby reducing ROS and inhibiting IL-13 production. Keap1-Nrf2 PPI-IN-2 can be used for research on atopic dermatitis.
-
Anti-IL-13 Antibody (C836)
0 ImagesCat. No.: HY-P991594Anti-IL-13 Antibody (C836) is a neutralizing monoclonal antibody targeting human IL-13. The Fab fragment of Anti-IL-13 Antibody (C836) is a heterodimer composed of heavy chains and light chains, each folded into variable and constant domains. Anti-IL-13 Antibody (C836) can be used for chronic inflammatory diseases, such as asthma.
-
PARP14 inhibitor 1
0 ImagesCat. No.: HY-172806CAS No.: 3035493-13-8PARP14 inhibitor 1 is an orally active, selective PARP14 inhibitor with an IC50 of 5.52 nM. PARP14 inhibitor 1 exhibits favorable pharmacokinetic properties and in vivo safety. PARP14 inhibitor 1 enhances and stabilizes intracellular endogenous PARP14 protein levels, while effectively reducing the expression levels of IL-4, IL-13 and IL-17A. PARP14 inhibitor 1 can be used in research related to atopic dermatitis.
-
Anti-CD1a Antibody (OKT-6)
0 ImagesCat. No.: HY-P990869Anti-CD1a Antibody (OKT-6) is an anti-human CD1a IgG1 monoclonal antibody. Anti-CD1a Antibody (OKT-6) blocks T cell activation by blocking CD1a function. Anti-CD1a Antibody (OKT-6) can reduce the production of IFN-γ. Anti-CD1a Antibody (OKT-6) can be used for researches on cancer and inflammation such as leukemia. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977).
-
APH003
0 ImagesCat. No.: HY-184915CAS No.: 3065495-08-8APH003 is an orally active IRAK4 PROTAC degrader with a DC50 of 0.74 nM in human peripheral blood mononuclear cells (hPBMCs). APH003 recruits IRAK4 to CRBN to form a ternary complex, mediates the ubiquitination and degradation of IRAK4 via the ubiquitin-proteasome pathway, and inhibits the kinase activity of IRAK4. APH003 inhibits LPS- or IL-1β/LPS-induced phosphorylation of ERK, JNK and NF-κB. APH003 inhibits the secretion of TNF-α, IL-6, IL-8 and IL-13 by stimulated hPBMCs. APH003 exhibits anti-inflammatory activity in rat TNBS-induced intestinal inflammation models and mouse IL-33-induced skin inflammation models. APH003 can be used in research related to inflammatory bowel disease and skin inflammation.
-
Envudeucitinibum hydrochloride
0 ImagesCat. No.: HY-153701S1CAS No.: 3009133-87-0Synonyms: Envudeucitinib hydrochloride; ESK-001 hydrochlorideEnvudeucitinibum (Envudeucitinib; ESK-001) hydrochloride is an orally active and selective TYK2 allosteric inhibitor with an IC50 range of 104-149 nM. Envudeucitinibum hydrochloride blocks JH1 catalytic activity by specifically binding to the JH2 domain of TYK2, thereby inhibiting downstream signaling pathways. Envudeucitinibum hydrochloride is used for research on plaque psoriasis, systemic lupus erythematosus, and other immune-mediated diseases.
-
DOTA-Pep-1L
0 ImagesCat. No.: HY-P11287DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [225Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research.
-
MEDI-7836
0 ImagesCat. No.: HY-P991259MEDI-7836 is a humanized monoclonal antibody inhibitor that targets the interleukin-13 receptor. MEDI-7836 is promising for research of inflammation-related diseases.
-
PDE4-IN-8
0 ImagesCat. No.: HY-144684CAS No.: 2415085-45-7PDE4-IN-8 (Example 5) is a potent PDE4 inhibitor with an IC50 of 0.93 nM for PDE4B2.PDE4-IN-8 has little effect on IL13 (IC50=4.04 nM), IL4 (IC50=36.33 nM), IFNy (IC50=2394 nM).
-
AVP-13358
0 ImagesCat. No.: HY-165484CAS No.: 459805-03-9AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses.
-
GNE-7056
0 ImagesCat. No.: HY-189477CAS No.: 1557236-81-3GNE-7056 is an orally active interleukin-2-inducible T-cell kinase (ITK) inhibitor with a Ki of 0.2 nM against human kinase, and exhibits high selectivity over LCK kinase. GNE-7056 inhibits PLCγ-1 phosphorylation, suppresses the production of IL-2, IL-4, IL-13 and TH2 cytokines, reduces CD4+ T-cell proliferation, and inhibits activation-induced cell death of CD4+ T cells by decreasing the abundance of FasL. GNE-7056 can be used in asthma-related research.
-
CSL-360
0 ImagesCat. No.: HY-P991648CSL-360 is a chimeric unconjugated IgG1 monoclonal antibody targeting CD123. CSL-360 efficiently prevents the binding of IL-3 to CD123, abolishing IL-3 induced cell proliferation. CSL-360 can be used for acute myeloid leukemia (AML) research.
-
Anti-inflammatory agent 89
0 ImagesCat. No.: HY-161815Anti-inflammatory agent 89 is a multi-target glucocorticoid-isothiocyanate hybrid with anti-inflammatory activity. Anti-inflammatory agent 89 releases hydrogen sulfide via its isothiocyanate group, inhibits antigen-induced mast cell degranulation, alleviates pulmonary inflammation, and suppresses bronchial hyperresponsiveness and airway fibrosis. Anti-inflammatory agent 89 can be used in asthma research.
-
ANB032
0 ImagesCat. No.: HY-P992182ANB032 is a human IgG4 kappa BTLA agonist monoclonal antibody. ANB032 inhibits activated T cell proliferation and reduces secretion of inflammatory cytokines. ANB032 can be used for the research of atopic dermatitis[1].
-
RV-6153
0 ImagesCat. No.: HY-124459CAS No.: 1628139-03-6RV-6153 is a potent and selective dual inhibitor of PI3Kδ and PI3Kγ, with IC50 values of 2.5 nM and 28 nM, respectively. RV-6153 dually inhibits PI3Kδ and PI3Kγ, blocking Akt phosphorylation, thereby inhibiting ROS production and cytokine release at the cellular level, and reducing neutrophil and macrophage accumulation in the airways in vivo. RV-6153 can be used in research on chronic obstructive pulmonary disease, asthma, and other inflammatory diseases.
-
Aloin (mixture of A&B) (Standard)
0 ImagesAloin (mixture of A&B) (Standard) is the analytical standard of Aloin (mixture of A&B) (HY-N6013). This product is intended for research and analytical applications. Aloin (mixture of A&B) is an orally active anthraquinone derivative isolated from Aloe vera. Aloin (mixture of A&B) mitigates airway impairment and exerts neuroprotective, anti-inflammatory, antioxidant, antibacterial, antifungal, antiviral and antitumor effects. Aloin (mixture of A&B) inhibits Clostridium histolyticum collagenase, granulocyte matrix metalloproteinases and human 20S proteasome. Aloin (mixture of A&B) upregulates the Nrf2/HO-1 pathway, suppresses the TGF-β/Smad2/3 pathway. Aloin (mixture of A&B) reduces IL-4/IL-5/IL-13 levels, and reverses oxidative stress markers (MDA, SOD, GSH). Aloin (mixture of A&B) can be used for research on chronic ulcers, burns, wounds, inflammatory and degenerative disorders, asthma and neuroblastoma.
